TARGT Indiegene® V2, is the next generation of its comprehensive genomic profiling (CGP) test for cancer biomarker testing.
4baseCare, a precision oncology company building genomic and clinical intelligence for diverse populations, announced the launch of TARGT Indiegene® V2, the next generation of its comprehensive genomic profiling (CGP) test for cancer biomarker testing.
The journey began on 15 August 2021, when 4baseCare launched the first Indiegene developed from insights generated through Indian tumour genomics and with the ambition of making comprehensive cancer profiling more accessible.
Five years of continuous innovation, clinical experience and genomic insights have now led to Indiegene V2.
With 2,206 genes, V2 significantly expands the genomic breadth of the original panel. More importantly, it introduces a different way of looking at cancer.
Cancer is more than a mutation. Tumours are driven by interconnected biological processes that influence growth, survival, DNA repair, immune evasion and progression. TARGT Indiegene® V2 brings this perspective into CGP through genomic coverage mapped across the Hallmarks of Cancer.
Key capabilities include:
- 2,206 genes for broad genomic profiling
- Hallmarks of Cancer-led coverage to understand the biology driving tumour behaviour
- Immunotherapy biomarkers like MSI and individualised Tumour Mutation Burden (iTMB) score with percentile scoring
- HRD scoring and comprehensive coverage of 36 HRR genes
- CNVs and 299 clinically relevant fusions, among the most extensive fusion coverage available in commercial CGP assays
“Indiegene V2 is not simply a larger gene panel. It represents a shift from looking for individual biomarkers to understanding the biology behind cancer. As we take Indiegene to more patients and clinicians across global markets, our ambition remains the same, which is to make comprehensive, meaningful precision oncology accessible across diverse populations.” said Hitesh Goswami, Co-founder & CEO, 4baseCare.
“Developed through 4baseCare’s experience in population-relevant oncology and now being taken to global markets, TARGT Indiegene® V2 represents the next chapter in our vision to build globally relevant precision-oncology solutions for diverse and historically underrepresented populations”, Kshitij Rishi, Co-Founder and COO, 4baseCare.
